parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in early spermatids	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 49	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 16837

IGSF10 in dopamine neurons, braak-0.10 (p 0.807) → +0.15 (p 0.697)receipt 16845
IGSF10 in microglia, braak-0.40 (p 0.288) → +0.44 (p 0.240)receipt 16844

receipt 16845: IGSF10 in dopamine neurons, braak

power: full sample +0.05 (p 0.847, n 18), 95% CI -0.43 to +0.50. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.03 (p 0.894, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.06 (p 0.814, n 18). could be the mix.
skeptic: leave-one-out range -0.06 to +0.18, sign flips 3; without severely affected donors +0.05 (p 0.847, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for IGSF10 in dopamine neurons.

case closed: nothing better to follow up.

receipt 16844: IGSF10 in microglia, braak

power: full sample +0.07 (p 0.794, n 18), 95% CI -0.41 to +0.52. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.06 (p 0.814, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.10 (p 0.696, n 18). could be the mix.
skeptic: leave-one-out range -0.06 to +0.22, sign flips 4; without severely affected donors +0.07 (p 0.794, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for IGSF10 in microglia.

case closed: nothing better to follow up.

loading the receipts